Kaisa Elomaa

Kaisa Elomaa

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2021 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
MSMarkku Savolainen
Markku Savolainen
AKAntti Karlsson
Antti Karlsson
SRSamppa Rohkimainen
Samppa Rohkimainen
ITIiro Toppila
Iiro Toppila
MLMariann I Lassenius
Mariann I Lassenius
KEKaisa Elomaa
Kaisa Elomaa
Background: Gaucher disease (GD) is a rare inherited multiorgan disorder, yet a diagnosis can be significantly delayed due to a broad spectrum of symptoms and lack of disease awareness. Recently, the prototype of a GD point-scoring system (PSS) was established by the Gaucher Earlier Diagnosis Consensus (GED-C) initiative, and more recently, validated in Gaucher patients in UK. In our study, the original GED-C PSS was tested in Finnish GD patients. Furthermore, the feasibility of point scoring large electronic health record (EHR) data set by data mining to identify potential undiagnosed GD cases was evaluated. Methods: This biobank study was conducted in collaboration with two Finnish biobanks. Five previously diagnosed Finnish GD patients and ~ 170,000 adult biobank subjects were included in the study. The original PSS was locally adjusted due to data availability issues and applied to the Finnish EHR data representing special health care recordings. Results: All GD patients had high levels of the biomarker lyso-Gb1 and deleterious GBA mutations. One patient was a compound heterozygote with a novel variant, potentially pathogenic mutation. Finnish EHR data allowed the retrospective assessment of 27–30 of the 32 original GED-C signs/co-variables. Total point scores of GD patients were high but variable, 6–18.5 points per patient (based on the available data on 28–29 signs/co-variables per patient). All GD patients had been recorded with anaemia while only three patients had a record of splenomegaly. 0.72% of biobank subjects were assigned at least 6 points but none of these potential “GD suspects” had a point score as high as 18.5. Splenomegaly had been recorded for 0.25% of biobank subjects and was associated with variable point score distribution and co-occurring ICD-10 diagnoses. Discussion: This study provides an indicative GED-C PSS score range for confirmed GD patients, also representing potential mild cases, and demonstrates the feasibility of scoring Finnish EHR data by data mining in order to screen for undiagnosed GD patients. Further prioritisation of the “GD suspects” with more developed algorithms and data-mining approaches is needed. Funding: This study was funded by Shire (now part of Takeda).

27 August 2022 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
MPMinja Pehrsson
Minja Pehrsson
HHHanna Heikkinen
Hanna Heikkinen
UWUlla Wartiovaara-Kautto
Ulla Wartiovaara-Kautto
SMSampo Mäntylahti
Sampo Mäntylahti
PBPia Bäckström
Pia Bäckström
KEKaisa Elomaa
Kaisa Elomaa
Autosomal recessive Gaucher disease (GD) is likely underdiagnosed in many countries. Because the number of diagnosed GD patients in Finland is relatively low, and the true prevalence is currently not known, it was hypothesized that undiagnosed GD patients may exist in Finland. Our previous study demonstrated the applicability of Gaucher Earlier Diagnosis Consensus point-scoring system (GED-C PSS; Mehta et al., 2019) and Finnish biobank data and specimens in the automated point scoring of large populations. An indicative point-score range for Finnish GD patients was determined, but undiagnosed patients were not identified partly due to high number of high-score subjects in combination with a lack of suitable samples for diagnostics in the assessed biobank population. The current study extended the screening to another biobank and evaluated the feasibility of utilising the automated GED-C PSS in conjunction with small nucleotide polymorphism (SNP) chip genotype data from the FinnGen study of biobank sample donors in the identification of undiagnosed GD patients in Finland. Furthermore, the applicability of FFPE tissues and DNA restoration in the next-generation sequencing (NGS) of the GBA gene were tested. Previously diagnosed Finnish GD patients eligible to the study, and up to 45,100 sample donors in Helsinki Biobank (HBB) were point scored. The GED-C point scoring, adjusted to local data, was automated, but also partly manually verified for GD patients. The SNP chip genotype data for rare GBA variants was visually assessed. FFPE tissues of GD patients were obtained from HBB and Biobank Borealis of Northern Finland (BB). Three previously diagnosed GD patients and one patient previously treated for GD-related features were included. A genetic diagnosis was confirmed for the patient treated for GD-related features. The GED-C point score of the GD patients was 12.5–22.5 in the current study. The score in eight Finnish GD patients of the previous and the current study is thus 6–22.5 points per patient. In the automated point scoring of the HBB subpopulation (N ≈ 45,100), the overall scores ranged from 0 to 17.5, with 0.77% (346/45,100) of the subjects having ≥10 points. The analysis of SNP chip genotype data was able to identify the diagnosed GD patients, but potential undiagnosed patients with the GED-C score and/or the GBA genotype indicative of GD were not discovered. Restoration of the FFPE tissue DNA improved the quality of the GBA NGS, and pathogenic GBA variants were confirmed in five out of six unrestored and in all four restored FFPE DNA samples. These findings imply that the prevalence of diagnosed patients (~1:325,000) may indeed correspond the true prevalence of GD in Finland. The SNP chip genotype data is a valuable tool that complements the screening with the GED-C PSS, especially if the genotyping pipeline is tuned for rare variants. These proof-of-concept biobank tools can be adapted to other rare genetic diseases.

9 October 2025 in Epilepsia
Verified
Journal Article
Open access
LWLine Kønig Wilms
Line Kønig Wilms
MLMorten I. Lossius
Morten I. Lossius
KAKaapo Annala
Kaapo Annala
JAJonas Abdel‐Khalik
Jonas Abdel‐Khalik
LFLena Fanter
Lena Fanter
JPJukka Peltola
Jukka Peltola
Objective: This study aimed to assess the performance of the Nelli seizure monitoring system in detecting and classifying seizures during sleep or while at rest in bed in patients with Lennox–Gastaut syndrome (LGS) and Dravet syndrome (DS). Methods: We conducted a non‐interventional, single‐center feasibility study from August 2023 to March 2024, involving 20 patients aged ≥2 years diagnosed with DS or LGS. Participants used Nelli for home‐based seizure monitoring during sleep or while at rest in bed for 4 weeks. Seizures were detected and classified by Nelli, and results were compared to epileptologist reviews and seizure diaries. Results: Of 20 enrolled patients, 14 (70%) who experienced seizures at rest were included in the analyses. Among them, Nelli detected 368 seizures, with an accuracy of 97.8%, as confirmed by independent reviewers. Eight seizures (2.2%) detected by Nelli were false positives, identified as part of a single seizure episode. Of the 14 patients, only 35.7% reported experiencing seizures in their diaries, and only 26.1% of the seizures were documented. Seizure durations ranged from 6 to 396 s, with considerable variation. Nelli demonstrated high accuracy in seizure classification (Gwet agreement coefficient [AC1] = .81–1.00) in nine of 14 cases. However, in three of 14 patients, moderate accuracy (AC1 = .41–.60) was observed due to challenges in classifying seizures in patients with high seizure frequency or suboptimal device positioning. The average classification accuracy of Nelli for tonic–clonic seizures was .99 (150/152 seizures), tonic seizures .55 (102/186), clonic seizures 1.00 (3/3), focal motor seizures .89 (16/18), and myoclonic seizures 1.00 (1/1). Significance: Nelli demonstrated high sensitivity and classification accuracy for detecting and categorizing seizures in bed in patients with DS and LGS, outperforming seizure diaries and providing a reliable tool for seizure monitoring in home settings.

16 July 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
SMSylvia MARTIN
Sylvia MARTIN
ÅGÅsa Grauman
Åsa Grauman
JCJoshua Coulter
Joshua Coulter
BHBesir Hasan
Besir Hasan
JVJorien Veldwijk
Jorien Veldwijk
JZJana Zschuentzsch
Jana Zschuentzsch
Background: The integration of Artificial Intelligence (AI) and algorithms into healthcare is transformative, particularly in diagnosing rare diseases (RDs), enhancing the accuracy and speed of condition identification. Objectives: This systematic literature review investigates perceptions and attitudes toward the use of AI in Electronic Health Records (EHRs) for screening patients at risk of RD, aiming to understand patients’ and healthcare providers’ expectations and concerns. Methods: Following PRISMA guidelines, a systematic search was performed in December 2023. A search strategy developed by the research team in collaboration with an expert librarian, using the PICO framework, was applied. Searches were conducted in PubMed, Scopus, and Web of Science. The search strategy covered four main concepts: diagnostic techniques, medical records, AI, and attitudes toward these technologies. Results: The initial search retrieved 3348 articles after duplicate removal. However, no studies met the inclusion criteria. As a result, no eligible studies were identified, preventing risk-of-bias assessment or data synthesis. Discussion: The absence of relevant studies highlights the need for further research focusing on patient and healthcare provider attitudes toward AI-integrated EHRs, especially in RD and their early detection. Conclusions: The lack of studies on stakeholder attitudes toward AI in EHRs for RD screening represents an important research gap. Addressing this gap will improve the understanding and development of AI applications in healthcare, ensuring they meet user needs and ethical standards.